Information Update - Health Canada Confirms License Suspension of Biolyse Pharma for Serious Manufacturing Concerns - Tucson News Now

Information Update - Health Canada Confirms License Suspension of Biolyse Pharma for Serious Manufacturing Concerns

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Health Canada

Supply of paclitaxel will not be disrupted for Canadian patients

OTTAWA, May 9, 2014 /CNW/ - Health Canada today confirmed it has suspended the establishment licence of Biolyse Pharma Corporation's facility in St. Catharines, Ont., because of significant concerns with the manufacturing process discovered during a recent inspection.

Injectable paclitaxel (6mg/ml), used in the treatment of certain lung and breast cancers, is currently the only drug produced at that facility.

The suspension of the establishment license means Biolyse is not permitted to sell paclitaxel from that facility to the Canadian market until the serious manufacturing concerns are fully addressed and the suspension on their establishment licence is lifted.

To receive and maintain an establishment licence in Canada, a company must comply with Good Manufacturing Practices (GMP), which help to ensure that the drugs sold in Canada are safe, effective and of high quality. These guidelines are applied to all companies and are widely known.

Health Canada has confirmed that supplies of paclitaxel are available from another manufacturer that is licenced to produce it in Canada. The Department is also in regular contact with the provinces and territories regarding the supply situation. There has been no supply disruption caused by the licence suspension.

In the short term, Health Canada is allowing the Biolyse product currently on the market to continue to be used for treatment. However, Health Canada cannot be assured that future supplies of paclitaxel from Biolyse would be safe and effective for use by patients until the serious manufacturing violations are resolved.

Patients currently being treated with paclitaxel from Biolyse should speak to their healthcare professional if they have concerns with their treatment.

Health Canada officials continue to work with the staff at Biolyse Pharma to resolve the issues identified during the inspection as quickly as possible.

©2012 PR Newswire. All Rights Reserved.

  • Latest Health NewsThe Latest from HealthDayMore>>

  • The 'Hobby Lobby ruling' and what it means for U.S. health care

    The 'Hobby Lobby ruling' and what it means for U.S. health care

    The U.S. Supreme Court's ruling on contraception coverage -- as mandated under the Affordable Care Act -- could lead to a legal quagmire that might allow companies to deny insurance coverage for any medical practice that violates their religious principles.
    The U.S. Supreme Court's ruling on contraception coverage -- as mandated under the Affordable Care Act -- could lead to a legal quagmire that might allow companies to deny insurance coverage for any medical practice that violates their religious principles.
  • Diet changes can alter gut bacteria

    Diet changes can alter gut bacteria

    Dietary changes can dramatically alter the balance of bacteria in the gut on a daily basis, according to a new study.
    Dietary changes can dramatically alter the balance of bacteria in the gut on a daily basis, according to a new study.
  • Lift U.S. ban on blood donations by gay men

    Lift U.S. ban on blood donations by gay men

    The United States should repeal a 30-year policy that bans blood donations from gay and bisexual men, according to a team of medical and legal experts writing this week in the Journal of the American Medical...
    The United States should repeal a 30-year policy that bans blood donations from gay and bisexual men, according to a team of medical and legal experts writing this week in the Journal of the American Medical Association.
Powered by WorldNow